Zoladex Alternatives Compared
| Zoladex | Norethindrone | Orilissa |
|
|---|
| Zoladex (goserelin) | Norethindrone | Orilissa (elagolix) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Prostate Cancer, Breast Cancer - Palliative, Endometriosis, Bleeding Disorder. Zoladex may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Amenorrhea, Abnormal Uterine Bleeding, Endometriosis, Birth Control. May also be prescribed off label for Gender Affirming Hormone Therapy . |
Prescription only
Prescribed for Endometriosis. Orilissa may also be used for purposes not listed in this medication guide. |
Related suggestions Endometriosis
Popular comparisons
|
|||||||||||||||||||||||
| More about Zoladex (goserelin) | More about Norethindrone | More about Orilissa (elagolix) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
No lower-cost generic available |
|||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Zoladex has an average rating of 6.8 out of 10 from a total of 93 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 20% reported a negative effect. |
Norethindrone has an average rating of 4.8 out of 10 from a total of 1508 ratings on Drugs.com. 32% of reviewers reported a positive effect, while 46% reported a negative effect. |
Orilissa has an average rating of 5.2 out of 10 from a total of 112 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 41% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
Common side effects include:
See also: Zoladex side effects in more detail. |
Commonly reported side effects include:
See also: norethindrone side effects in more detail. |
See also: Orilissa side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Zoladex prices |
View all norethindrone prices |
View all Orilissa prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other goserelin brands include: Zoladex 3-Month | Affodel, Camila, Deblitane, Emzahh, Errin, Heather, Incassia, Jencycla, Lyleq, Lyza, Nor-QD, Norlyda, Norlyroc, Sharobel, Tulana View more |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
4.2 hours |
10 hours |
6 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 275 drugs are known to interact with Zoladex:
|
A total of 242 drugs are known to interact with norethindrone:
|
A total of 342 drugs are known to interact with Orilissa:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
July 30, 2012 |
July 23, 2018 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.